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Background: Celiac disease is present in ~1% of the general population in the United States and Europe. Despite
the availability of inexpensive serologic screening tests, ~85% of individuals with celiac disease remain undiagnosed
and there is an average delay in diagnosis of symptomatic individuals with celiac disease that ranges from ~5.8-11 years.
This delay is often attributed to the use of a case-based approach for detection rather than general population screening
for celiac disease, and deficiencies at the level of health care professionals. This study aimed to assess if patient-centered
barriers have a role in impeding serologic screening for celiac disease in individuals from populations that are
clinically at an increased risk for celiac disease.
Methods: 119 adults meeting study inclusion criteria for being at a higher risk for celiac disease were recruited
from the general population. Participants completed a survey/questionnaire at the William K. Warren Medical
Research Center for Celiac Disease that addressed demographic information, celiac disease related symptoms
(gastrointestinal and extraintestinal), family history, co-morbid diseases and conditions associated with celiac
disease, and patient-centered barriers to screening for celiac disease. All participants underwent serologic screening for
celiac disease using the IgA tissue transglutaminase antibody (IgA tTG) and, if positive, testing for IgA anti-endomysial
antibody (IgA EMA) as a confirmatory test.
Results: Two barriers to serologic testing were significant across the participant pool. These were participants not
knowing they were at risk for celiac disease before learning of the study, and participants not knowing where to get
tested for celiac disease. Among participants with incomes less than $25,000/year and those less than the median age,
not having a doctor to order the test was a significant barrier, and this strongly correlated with not having health
insurance. Symptoms and co-morbid conditions were similar among those whose IgA tTG were negative and those
who tested positive.
Conclusion: There are significant patient-centered barriers that impede serologic screening and contribute to the
delayed detection and diagnosis of celiac disease. These barriers may be lessened by greater education of the public
and health care professionals about celiac disease symptoms, risk factors, and serologic testing.
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Celiac disease is characterized by small intestinal mucosal
damage and nutrient malabsorption. Disease is activated
in genetically susceptible individuals by dietary exposure
to gluten, the term commonly used for nitrogen-rich stor-
age proteins found in wheat, barley, and rye.
Celiac disease affects approximately 1% of the popula-
tion in the U.S. (i.e. ~ 2.3 million) whereas its prevalence
in the countries in Europe varies from ~0.3% in Germany
to ~2.4% in Finland [1]. Celiac disease is common in parts
of North Africa and areas of the Middle East [2], but it is
rare in the Japanese population consistent with a marked
underrepresentation of the major human leukocyte anti-
gen (HLA) DQ alleles that are required for disease suscep-
tibility [3-5].
Celiac disease can present with gastrointestinal tract
symptoms, a wide array of extraintestinal manifestations,
or both [6]. Gastrointestinal symptoms frequently include
increased gas and bloating, abdominal pain, chronic
diarrhea or constipation, and weight loss, whereas extrain-
testinal manifestations frequently include iron deficiency
with or without anemia, an unexplained decrease in bone
density or premature onset osteoporosis, unexplained in-
creases in liver transaminases, depression, chronic fatigue,
peripheral neuropathy, aphthous stomatitis, unexplained
infertility, and dental enamel defects.
Individuals with a high risk for celiac disease include
first-degree, and to a lesser extent second degree, relatives
of patients with celiac disease [7,8]. In addition, individuals
with co-morbid diseases such as type I diabetes mellitus,
autoimmune thyroid disease, dermatitis herpetiformis,
Sjogren’s disease, microscopic colitis, and autoimmune
liver disease have an increased prevalence of celiac dis-
ease [8,9]. Celiac disease has also been reported to be
increased in those with dental enamel hypoplasia [10],
cerebellar ataxia [11], and migraine headaches [12], and
in a subset of individuals with irritable bowel syndrome,
although the latter has been controversial [13].
Current guidelines recommend screening for celiac dis-
ease by assaying for serum IgA antibodies to the enzyme
tissue transglutaminase 2 (IgA tTG) [14,15]. The IgA anti-
endomysial antibody (EMA) test often is used as a follow
up confirmatory test [8]. Esophagogastroduodenoscopy
with small intestinal mucosal biopsy is the current gold
standard for diagnosis in adults, although recent guide-
lines from the European Society of Pediatric Gastroenter-
ology, Hepatology, and Nutrition endorse the diagnosis
of celiac disease in some children in the absence of
small intestinal mucosal biopsy [16].
Case finding in adults at high risk for celiac disease using
serologic tests was recommended by a National Institutes
of Health (NIH) Consensus Conference on Celiac Disease,
the American Gastroenterology Association (AGA), and
by the American College of Gastroenterology (ACG)[15,17,18]. In symptomatic patients with celiac disease,
early diagnosis and treatment with a strict gluten free
diet alleviates most symptoms, decreases morbidity and
mortality, and is associated with an improved quality of
life [19-21]. It is less clear if there is an improvement in
quality of life and a mortality benefit to early diagnosis
and treatment of screening detected asymptomatic indi-
viduals with celiac disease [9,22,23].
Epidemiologic studies estimate that the prevalence of
celiac disease may have increased by as much as four-
fold since 1954 [23]. Moreover, as many as 85% of indi-
viduals with celiac disease have not been detected and
diagnosed [24]. Among diagnosed celiac disease patients,
the average time from symptom onset to diagnosis has
ranged from 5.8 to 11 years despite the availability of
sensitive and specific serologic screening tests [19,20,25].
Further, patients may carry erroneous diagnoses during
those years until a correct diagnosis is made. In addition
to morbidities associated with undiagnosed symptomatic
patients, those with undiagnosed celiac disease were re-
ported to have a higher mortality rate than those with
negative serology for celiac disease [23,26].
Reasons for the marked under-diagnosis of celiac dis-
ease among individuals in the general population who
are clinically at an increased risk for celiac disease have
not been explored. Patients that have been diagnosed
with celiac disease often cite perceived deficiencies in
the health care system. These include, for example, a
lack of physician and health care provider awareness of
the wide array of symptoms and presentations of celiac
disease, its association with other diseases, and current
serologic screening options [27]. We hypothesized that
patient-centered barriers to screening for celiac disease
also play an important role in the under-detection and
-diagnosis of celiac disease. We report herein on patient-
centered barriers to antibody based screening for celiac
disease among clinically high-risk individuals recruited
from the general population.
Methods
Recruitment and selection of the study population
Potential study participants were recruited through flyers
posted in local supermarkets, community health clinics,
community centers, on the University of California, San
Diego (UCSD) college campus, and on local celiac dis-
ease websites (see flyer, Additional file 1). The flyer indi-
cated researchers at the William K. Warren Medical
Research Center for Celiac Disease at UCSD were “seek-
ing individuals who may have celiac disease to partici-
pate in a research study to investigate reasons for poor
diagnosis rates among individuals who are at high risk
for celiac disease”. Individuals over age 18 wanting more
information and to see if they qualified for participation
in the study were instructed to download an application
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Research Center for Celiac Disease Clinical Studies Office
via the web or telephone. Respondents were informed that
the study involved providing a serum sample and com-
pleting a study questionnaire at UCSD. Those interested in
participating in the study were provided a brief written ap-
plication (Additional file 2) and following its submission
underwent a standardized telephone screen by the clinical
study coordinator to ascertain that they met study inclu-
sion criteria or had exclusion criteria (see Additional file 3).
Inclusion criteria required the applicant to have at least
one qualifying risk factor for celiac disease and at least
one potential barrier to diagnosis (see list of qualifying
risk factors and potential barriers to diagnosis in Lists 1
and 2, respectively, below). Criteria for determining if in-
dividuals were at high risk for celiac disease were devel-
oped according to AGA guidelines [15]. Individuals
were excluded if they had been screened with a “blood
test” for celiac disease in the past five years, had ex-
cluded gluten from the diet within the past month, or if
a 24 hour diet history indicated they were consuming
minimal gluten in the diet. Individuals reporting they
had been tested with a fecal, skin or sputum test for ce-
liac disease were not excluded since such tests have not
been validated for celiac disease screening. The research
team made a final decision for inclusion or exclusion of
each applicant after review of the written application
and telephone interview information.
List 1 Qualifying risk factors
Gastrointestinal risk factors (>4 weeks and
impairing quality of life)
Chronic diarrhea
Recurrent abdominal pain








Liver disease (autoimmune, primary biliary cirrhosis, or
unexplained cause for abnormal liver tests)
Type 1 diabetes mellitus
Anemia not responsive to iron therapy
Other
Family history of celiac disease (1st or 2nd degree relative)
List 2 Qualifying potential barriers to diagnosis
I did not know where to be tested
I did not know about celiac disease before learning
about the studyI did not know I was at risk for celiac disease before
learning about the study
I do not have a physician
I was not been motivated to be tested until recently
My doctor does not know which test to order
I don’t have insurance
My doctor will not test me
I did not want to see a doctor to be tested
I do not want my insurance company to know the
results
I did not have symptoms so I did not want to be tested
I can’t afford the cost or co-payment
I have been scared to be tested until recently
I was tested for celiac disease with a skin/fecal/saliva
test and did not know I should get a blood test
I cannot take time off work to be tested
One hundred nineteen applicants met inclusion cri-
teria (84% of telephone screened individuals) and 22
applicants (16%) were excluded according to the study
exclusion criteria after the telephone interview. All 119
applicants accepted into the study kept their scheduled
appointments for serologic testing and completed a
self-administered study survey (Additional file 4) at the
UCSD Clinical Research Center.
Members of the William K. Warren Medical Research
Center at UCSD designed the study protocol. Questions
for an initial pilot study questionnaire were developed
by the authors with additional input from a volunteer
focus group provided from the membership of the local
San Diego chapter of the Celiac Support Association
(CSA), the Celiac Disease Foundation (CDF), and mem-
bers of the Warren Center Community Advisory Board.
The latter groups suggested the addition and/or deletion
of questions, and the rewording of questions based, in
large measure, on what these individuals viewed from
personal experience as barriers that occurred during the
process of obtaining the diagnoses of celiac disease.
An initial pilot study carried out by the Warren Center
(S. McNally and M.F. Kagnoff, unpublished data) revealed
areas for improvement in the study design, information
sought in the telephone interview process, and clarity of
the finally adopted questionnaire. No participants in the
pilot study were included in the present study. The final
questionnaire provided the option for participants to add
other barriers they experienced that were not listed in the
questionnaire. The UCSD Institutional Review Board ap-
proved these investigations.
Serologic tests
Each participant donated a blood sample drawn at UCSD
that was assayed for IgA tTG levels by enzyme-linked
immunosorbent assay at Prometheus Laboratories, San
Diego, California, and samples testing positive were














High School/GED 11 (9%)
Some college 35 (30%)
4 year degree 37 (31%)






White non Hispanic 94 (79%)
Other 9 (7.5%)
*Includes unemployed able to work, unemployed not able to work, retirees,
homemakers, students, and non-paid volunteers.
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measured, per current clinical guidelines, as IgA defi-
ciency has not been deemed common enough to war-
rant routine testing unless there is otherwise reason to
suspect it [8]. Participants were notified of serologic
test results and interpretation of the results by mail in
accordance with requirements and approval of the
UCSD Institutional Review Board. All subjects were en-
couraged to consult a physician regarding their symp-
toms and the test results.
Statistical analysis
Statistical analysis of the barriers to screening was per-
formed across the total participant group and compo-
nents of the demographic subgroups using the Wilcoxon
Rank Sum Test. Specifically, the five point Likert-scale
responses were submitted to the Wilcoxon Rank Sum
Test with one-sided alternative hypothesis median μ>3
(“agree” or “strongly agree”). Fisher’s Exact Test was
used to assess the strength of the association between
each barrier and demographic categories (i.e., sex, level
of education, and income). P-values ≤ 0.05 were consid-
ered significant. Spearman’s rank correlation coefficient
was used to assess the correlation between each barrier.
Bias-corrected and accelerated bootstrap with 1000 rep-
licates was used to estimate 95% confidence intervals for
Spearman’s rank correlation [28].
Results
Demographics of the study population are shown in
Table 1. The mean and median age of participants was
40.9 (range 19–78) and 34.9 years respectively, with a
3:1 female to male ratio that approximates the female
sex predominance in celiac disease diagnosed in adult
populations [12,19,29,30]. There was no significant dif-
ference in income or education level or ethnicity be-
tween female and male participants. Annual income of
participants ranged from less than $25,000 USD to
greater than $100,000 USD. Approximately 2/3rds of par-
ticipants were employed outside the home, 8% were stu-
dents and 7% were retired. A majority of participants
self-identified as White/non-Hispanic (79%) or Hispanic
(13.4%). The remaining participants were Asian (3),
Black (3), Arab/Middle Eastern (2), or Indian (1). Thirty-
three participants reported having a first-degree family
member with celiac disease, 18 of which were reported
to be biopsy-proven. The majority of participants
learned of the study from seeing the flyer in a grocery
store, on the internet, or from friends or family members
who saw the flyer. Interestingly, none of the patients re-
ported learning of the study from flyers posted at com-
munity health clinics.
Participant reported gastrointestinal and extraintesti-
nal symptoms/findings on the survey are shown inTable 2. The spectrum of symptoms closely resembled
that reported by patients with documented celiac disease
patients prior to diagnosis [12], and in the majority of
participants the reported symptoms were present for
more than six months. The most common gastrointestinal
symptoms were gas and bloating, abdominal cramping or
pain, diarrhea or constipation, nausea, and mouth sores.
More than 1/3rd of participants reported extraintestinal
symptoms that included fatigue, muscle cramps or pain,
joint pain, numbness or tingling in the fingers or toes (i.e.
paresthesias), symptoms of depression or anxiety, recur-
ring headaches or migraines, pruritic skin rashes, and
bone pain. The most frequently cited co-morbid health
problems were depression, irritable bowel syndrome,
iron-deficiency anemia and autoimmune thyroid disease
(Table 3). Subjectively, most participants regarded their
health as good to excellent (7% excellent, 34% very
good, 44% good, 12% fair, and 3% poor).
Two barriers were statistically significant for the popu-
lation studied: “I did not know where to get tested”, and
“I did not know I was at risk for celiac disease” (Table 4).
Further, more than 1/3rd of participants either strongly
Table 3 Frequency of co-morbid health problems
Co-morbid health problems N (%)
Depression (diagnosed) 37 (31.1)
*Irritable Bowel Syndrome (IBS) 32 (26.9)
Anemia caused by iron deficiency 25 (21.0)
*Autoimmune thyroid disease 19 (16.0)
Anemia of unknown cause 15 (12.6)
Chronic fatigue syndrome 11 (9. 2)
Fibromyalgia 11 (9.2)
*Bone disease, osteoporosis, or low bone
density before age 50
9 (7.6)
*Unexplained infertility 8 (6.7)
Anemia caused by B12 or folate deficiency 7 (5.9)
*Sjogren’s syndrome 3 (2.5)
*Dermatitis herpetiformis 2 (1.7)
*Autoimmune hepatitis 1 (0.8)
Crohn’s disease or ulcerative colitis 1 (0.8)
Addison’s disease 0 (0)
Anemia caused by something other than B12,
folate, or iron deficiency
0 (0)
Cryptogenic liver disease 0 (0)
IgA deficiency 0 (0)
Systemic lupus erythematosus (SLE) 0 (0)
*Primary biliary cirrhosis 0 (0)
Primary sclerosing cholangitis 0 (0)
*Type 1 insulin dependent diabetes 0 (0)
*Unexplained elevated transaminase levels 0 (0)
*Health problems used to qualify individuals for participation in the study.
Table 2 Frequency of symptoms
Symptom N (%)
*Gas and bloating 103 (87.3)




Muscle cramps/pain 71 (60.2)
Joint pain 68 (57.6)
Numbness or tingling in fingers or toes 62 (52.5)
Symptoms of depression 58 (49.6)
Anxiety 57 (48.3)
Recurring headaches or migraines 56 (47.9)
Nausea 50 (42.7)
Itchy skin rash 49 (41.9)
Mouth sores 40 (33.9)
Bone pain 39 (33.1)
Poor dental enamel formation 26 (22.2)
Weight loss (unintentional) 20 (17.1)
Vomiting 13 (11.1)
Infertility 12 (10.3)
Translucent-looking teeth 11 (9.5)
Seizures 3 (2.6)
Other 20 (16.8)
*Symptoms/signs used to qualify individuals for inclusion in the study if
persisting for more than four weeks.
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where to get tested” (60.5%), “I did not know anything
about celiac disease until recently” (52.6%), “I did not
know I was at risk for celiac disease” (50.9%), “I do not
have a doctor to order the test” (47.5%), “I was not moti-
vated to get tested until recently” (41.7%), “I have a doc-
tor, but I do not think he/she knows what test to order”
(35.3%), “I knew that I may be at risk for celiac disease,
but I did not know there was a screening test available”
(34.7%), and “I have no insurance coverage to take care
of the costs” (33.7%), whereas barriers which were cited
by less than 10% of the participants were, “I do not want
my health insurance company to know the results of the
test”, “I do not have any symptoms and so have not
wanted to get tested”, “I have insurance, but cannot af-
ford co-payment for the test”, “I have been scared to get
tested until recently or did not want to know the re-
sults”, “I was tested with a skin/fecal/saliva test and did
not know that I should get the blood test”, “I cannot
take time off from work to get tested at a doctor’s of-
fice”, and “I was told before that I did not need to get
tested because of my race or ethnicity” (Figure 1).Several barriers were statistically significant for specific
demographic groups (Table 5). In addition to not know-
ing where to get tested, those younger than the median
age of 34.9 years were significantly more likely to not
have a doctor than those older than the median age. Fur-
ther, not knowing where to get tested, which was a sig-
nificant barrier across the entire participant group, was
highly significant among women (p ≤ 0.001, N = 91) but
not in men (P = 0.314; N = 28).
Those with annual incomes less than $25,000 differed
from the higher income groups in that 65% indicated
they did not have a doctor to order the test (P = 0.007),
whereas the lack of a doctor to order the test was not a
statistically significant barrier for the other income groups
(Table 5). Consistent with that, 61.1% of individuals in the
lowest income group cited the lack of health insurance as
a barrier to testing (p = 0.06; N = 35). Not knowing where
to be tested was a significant barrier for those in the low-
est two income categories whereas not knowing they were
at risk was a significant barrier among those in the
$50,000-$100,000 annual income group. Although none
of the barriers tested was statistically significant among
Table 4 Frequency of barriers to screening
Barrier statements N SA1 (%) A (%) N (%) D (%) SD (%) P-value2
I did not know where to get tested. 119 23.5 37.0 17.7 9.2 12.6 <0.001
I did not know I was at risk for celiac disease. 118 21.2 29.7 17.8 17.0 14.4 0.028
I did not know anything about celiac disease until recently. 118 21.2 31.4 11.9 18.6 17.0 0.075
I do not have a doctor to order the test. 118 21.2 26.3 12.7 16.1 23.7 0.450
I was not motivated to get tested until recently. 118 16.1 25.6 9.3 16.1 22.9 0.477
I have no insurance coverage to take care of the costs. 119 21.9 11.8 8.4 22.7 35.3 0.990
I have a doctor, but I do not think he/she knows what test to order. 116 10.3 25 19.9 15.5 29.3 0.995
I knew that I may be at risk for celiac disease, but I did not know
there was a screening test available.
118 11.0 23.7 17.0 20.3 28.0 0.995
I have a doctor, but he/she will not test me. 117 7.7 13.7 24.8 23.1 30.8 >0.999
I do/did not want to see a doctor for testing. 118 2.5 13.6 20.3 30.5 33.1 >0.999
I have been scared to get tested until recently or did not want to
know the results.
118 1.7 5.1 17.0 36.4 39.8 >0.999
I do not have any symptoms and so have not wanted to get tested. 119 0.8 7.6 14.3 31.9 45.4 >0.999
I do not want my health insurance company to know the results of the test. 118 0.8 7.6 20.3 18.6 55.1 >0.999
I have insurance, but cannot afford co-payment for the test. 118 3.4 3.4 14.4 24.6 54.2 >0.999
I was tested with a skin/fecal/saliva test and did not know that I should
get the blood test.
117 0.9 5.1 13.7 22.2 58.1 >0.999
I was told before that I did not need to get tested because of my
race or ethnicity.
118 0 1.7 16.1 27.1 55.1 >0.999
I cannot take time off from work to get tested at a doctor’s office. 118 0 2.5 12.7 30.5 54.2 >0.999
1SA = Strongly agree; A = Agree; N = Neither; D = Disagree; SD = Strongly disagree.


















0 20 40 60 80
Was told not to be tested due to race/ethnicity
Cannot take time off from work for testing
Was tested with a skin/feval/saliva test
Scared to be tested
Cannot afford co-payment
I do not have any symptoms
Don't want insurance company to know results
Do/did not want to see a doctor for testing
My doctor will not test me
No insurance coverage to take care of the costs
Did not know a screening test was available
Do not think my doctor knows what test to order
Was not motivated to be tested until recently
Do not have a doctor to order the test
Did not know I was at risk for celiac disease
Did not know anything about celiac disease
Did not know where to get tested
Percent Agreeing or Strongly Agreeing
Figure 1 Percent of participants reporting each patient-centered barrier to diagnosis.
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Table 5 Significant barriers by demographic
sub-population
Sub-population N Significant barriers P-value
Median age (years)
<34.9 60 I did not know where to get tested. 0.003
I do not have a doctor to order the
test.
0.008
>34.9 59 I did not know where to get tested. 0.012
Sex
Males 28 None >0.05
Females 91 I did not know where to get tested. <0.001




<$25,000 34 I do not have a doctor to order the
test.
0.007
I did not know where to get tested. 0.021
$25,000-$50,000 33 I did not know where to get tested. <0.001
$50,000-$100,000 31 I did not know I was at risk for celiac
disease.
0.035
>$100,000 16 None >0.05
Education
High school/GED 11 None >0.05
Some college 35 I did not know where to get tested. 0.031
4 year degree 37 I did not know where to get tested. 0.013
I did not know I was at risk for celiac
disease.
0.043
Graduate degree 35 I did not know I was at risk for celiac
disease.
0.027
I did not know where to get tested. 0.034
Employment
Employed 77 I did not know anything about celiac
disease until recently.
0.003
I did not know where to get tested. 0.004
I did not know I was at risk for celiac
disease.
0.012




94 I did not know where to get tested. 0.004
Hispanic 16 I did not know I was at risk for celiac
disease.
0.025
Other 9 I did not know I was at risk for celiac
disease.
0.015
I did not know anything about celiac
disease until recently.
0.048
*Includes unemployed able to work, unemployed not able to work, retirees,
homemakers, students, and non-paid volunteers.
Barbero et al. BMC Gastroenterology 2014, 14:42 Page 7 of 11
http://www.biomedcentral.com/1471-230X/14/42those with annual incomes above $100,000 (Table 5),
50% of this income group cited a lack of motivation as a
barrier to testing (p = 0.165; N = 16) making lack of mo-
tivation the most common barrier cited by this group.
Not knowing where to be tested was a significant bar-
rier across all education levels except High School/GED,
which did not have any statistically significant barriers,
possibly reflecting the small sample size (Table 5). The
most common barrier reported by the High School/GED
demographic group was, “I did not know anything about
celiac disease until recently”, with 8 out of 11 partici-
pants agreeing. A significant number of individuals with
all other levels of education reported, “I did not know
where to get tested” (Table 5). “I did not know I was a
risk for celiac disease” was a significant barrier only for
individuals with a four-year college or graduate degree.
Employed individuals and the unemployed faced an
overlapping barrier in that both did not know where to
get tested (Table 5), whereas only the employed signifi-
cantly reported not knowing anything about celiac dis-
ease until recently and not knowing they were at risk for
celiac disease.
Not knowing where to get tested was a significant bar-
rier among White participants whereas not knowing
they were at risk for celiac disease was a significant bar-
rier among Hispanic participants. A significant number
of individuals of other races/ethnicities reported not
knowing they were at risk for celiac disease and not
knowing about celiac disease until recently.
Strong correlations were found between several bar-
riers suggesting validity of the questionnaire (Table 6).
Subjects who reported “not knowing anything about ce-
liac disease until recently” were also likely to cite that
they did not know they were at risk for celiac disease.
Individuals without insurance were also likely to cite the
lack of a doctor to order the blood test, and individuals
who did not know there was a screening test available
also did not know where to get tested.
Of 119 participants, three (2.5%) had a positive IgA
tTG test (Table 7). All three identified themselves as
White, non-Hispanic. In each case, levels were >3-fold
greater than the upper limit of the laboratory’s range of
normal, and each also tested positive by the confirma-
tory IgA EMA test. Two of three serologically positive
participants reported they had at least one first-degree
family member with biopsy-proven celiac disease. Their
qualifying risk factors, cited barriers, symptoms, and co-
morbid health problems were not distinguishable from
those of the other 116 participants, who all had IgA tTG
titers well below the laboratory cutoff values for normal.
Discussion
We report there are significant patient-centered barriers
that impede serologic screening and contribute to the
Table 6 Significant correlations between barriers
Barrier A Barrier B Correlation coefficient 95% confidence interval
Did not know about celiac disease Did not know I was at risk 0.726 0.599 to 0.817
Do not have insurance Do not have a doctor to order test 0.475 0.288 to 0.618
Did not know about screening test Did not know where to get tested 0.364 0.175 to 0.531
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nosis of celiac disease is delayed from 5.8 to 11 years on
average after the onset of symptoms [19,20,25]. This is the
case despite readily available inexpensive serologic screen-
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celiac disease. Participants had a sex ratio that paralleled
that found among diagnosed celiac disease patients,
symptoms and co-morbidities typical of those found in
diagnosed celiac disease patients and a broad range of
income and education levels [6,12,19,23].
We reasoned a priori that key patient-centered barriers
would relate to a lack of knowledge about celiac disease
and serologic testing. This proved to be the case as the
most significant barriers among the participant group
were, “I did not know I was at risk for celiac disease”
and “I did not know where to get tested”. Although our
study was powered to find significant barriers that affect
the entire participant group, we cautiously point out sev-
eral barriers that were found in some of the demographic
subgroups and may indicate worthwhile avenues for fur-
ther research or outreach. Regarding access to healthcare,
for example, not having a doctor was a significant barrier
among those with annual incomes less than $25,000 and
those in the younger half of participants. Consistent with
this, not having health insurance strongly correlated with
participants not having a doctor. It remains to be seen to
what extent recent changes in health care laws will in-
crease the number of Americans with both insurance and
a doctor, and if this will lead to a higher frequency of test-
ing among individuals in those demographic groups.
Lack of knowledge among the public about celiac dis-
ease, its symptoms, and risk factors represented an import-
ant barrier to diagnosis. More than 50% of participants
reported not knowing anything about celiac disease until
recently or not knowing that they were at risk for celiac
disease. As a result, at-risk patients seeing a doctor for their
symptoms would be unlikely to question their physicians
about celiac disease or request serologic testing. Interest-
ingly, more than a third of participants did not think their
doctor would know which test to order, suggesting low pa-
tient confidence in physician knowledge about celiac dis-
ease. Consistent with that, primary care doctors, who form
the front line for detection of probable celiac disease, were
in fact found to have limited knowledge of the symptoms,
natural history, and methods of testing for celiac disease,
implying that greater education of health care professionals
about celiac disease would be beneficial [33]. To address
both problems, the National Institute of Health launched a
campaign in 2006 to increase celiac disease awareness
among health-care professionals and the public [34]. In
addition, the growing presence of gluten-free food prod-
ucts in grocery stores, gluten-free options on restaurant
menus, and articles about celiac disease and non-celiac
gluten sensitivity in the lay press also may help to increase
public awareness and the patient-physician conversation
on this topic.
A lack of motivation to get tested for celiac disease was
self-reported in more than 40% of participants and wasthe most common barrier cited by those in the highest in-
come group. Nonetheless, each participant possessed suffi-
cient motivation to contact the Warren Medical Research
Center for Celiac Disease after seeing our posted flyers,
engage in a telephone screening process, and, if qualified,
complete the study. Study completion required the time
and the cost of travel to the UCSD campus, the time taken
to complete a 20–30 minute questionnaire, and the dona-
tion of a blood sample for celiac serology. This level of
motivation likely exceeds that in the general population.
Individuals with celiac disease present with a spectrum
of intestinal and extraintestinal symptoms. Many of these
symptoms are not debilitating, and patients often learn to
“live with” their symptoms despite a decreased quality of
life. This is consistent with 85% of the participants rating
their overall health as good to excellent and may help
explain a lack of motivation for testing. Although 10
participants claimed to not have symptoms at the time
of the screening telephone interview, each of them re-
ported symptoms consistent with celiac disease on our
questionnaire.
Three of 119 (2.5%) of participants enrolled in the
study, or roughly 1:40, tested positive for IgA tTG. This
is consistent with a prior study in which 1 in 56 (1.7%)
symptomatic individuals tested had positive serology,
compared to 1:133 (0.7%) of the general population [6].
The fact that 2/33 (6%) of our participants who indicated
they had a first degree relative with celiac disease tested
positive for IgA tTG is consistent with the reported
prevalence of celiac disease in 5-10% of first-degree rela-
tives of celiac disease probands [7,31]. The 3 serologic-
ally positive individuals in our study would be classified
as presumptive celiac disease according to AGA criteria
[8], since small intestinal mucosal biopsy was not in-
cluded as part of this barriers research study. We do not
know whether any of the participants with symptoms
and negative IgA tTG values have non-celiac gluten sen-
sitivity [18,35,36].
AGA, ACG, and NIH recommendations favor active
case-finding, rather than general population screening
[8,17,18]. This strategy is more cost-effective as it in-
creases the pretest probability and therefore the rate of
positive testing, leading to fewer unnecessary procedures
[9]. However, such guidelines leave the question as to
whom to screen open to clinical discretion as many
common symptoms and co-morbidities are associated
with an increased prevalence of celiac disease. For ex-
ample, a study using an active-case finding strategy to
screen for celiac disease reported that 64% of survey re-
spondents met the criteria for celiac screening [37]. This
strategy will also miss many individuals with asymptom-
atic celiac disease and those with atypical symptoms.
Notably, the case-finding strategy thus far has failed to de-
tect and diagnose a large majority of individuals with
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whether celiac disease is an appropriate disease for mass
screening consistent with World Health Organization cri-
teria [9]. Nonetheless, it is clear that new improved testing
strategies for celiac disease appropriate for application in
the general or select populations are required.
Several limitations of this study are worth noting. We
powered the study to find significant barriers overall,
and this limited the ability to definitively delineate some
of the barriers within distinct demographic subgroups.
Participants were not a random sample from high celiac
disease prevalence populations. We designed the study
such that participants were individuals from the general
population who met criteria for being at a higher risk for
celiac disease than those in the general population at
large. Further, the study did not accurately reflect the
ethnic populations residing in San Diego County as it in-
cluded 13.4% of participants who self-identified as His-
panic, compared to the 33% of residents of San Diego
County who reported as Hispanic by census [38]. Finally,
we note that large prevalence studies have reported
roughly equal numbers of men and women with celiac
disease [6,23]. Nonetheless, women are more frequently
diagnosed with celiac disease than men at a rate of
roughly 3:1, and the population of women and men who
volunteered for this study was consistent with that ratio
[12,19,29,30]. This female predominance may reflect a
greater likelihood for women to seek medical attention for
their symptoms or press their physicians for celiac testing.
In this study, our advertising strategy (e.g. in grocery
stores) may have reached more women than men.
Conclusions
The under-detection and diagnosis of celiac disease may
be partially explained by patient-centered barriers related
to lack of knowledge regarding celiac disease symptoms,
risk factors, and screening tests. Many individuals face
barriers secondary to poor access to healthcare as well.
Future public awareness campaigns, improved access to
healthcare, and the development of cheaper and more
accurate modes of testing have the potential to increase
the rate of diagnosis of this common chronic disease.
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